GDF-15 at Admission Predicts Cardiovascular Death, Heart Failure, and Bleeding Outcomes in Patients with CAD

AIMS: We aimed to investigate the independent associations between growth differentiation factor 15 (GDF-15) level at admission and cardiovascular (CV) death, thrombotic events, heart failure (HF), and bleeding outcomes in patients with coronary artery disease (CAD). METHODS AND RESULTS: We measured the plasma concentrations of GDF-15 centrally in patients from the BIomarker-based Prognostic Assessment for patients with Stable angina and acute coronary Syndrome (BIPass) registry, which consecutively enrolled patients with CAD from November 2017 to September 2019 at five tertiary hospitals in China. The outcomes included CV death, thrombotic events myocardial infarction (MI) and ischaemic stroke, HF events acute HF during hospitalization and hospitalization for HF post-discharge (A/H HF) and cardiogenic shock, and bleeding outcomes non-coronary artery bypass grafting-related major bleeding and clinically significant bleeding (CSB) during the 12 month follow-up period after hospitalization. Among 6322 patients with CAD 65. 4% male, median age 63. 7 inter-quartile range (IQR) 56. 0-70. 1 years, the median concentration of plasma GDF-15 at admission was 1091 (IQR 790. 5-1635. 0) ng/L. Higher concentrations of GDF-15 were associated with an increased risk of CV death hazard ratio (HR) 1. 98, 95% confidence interval (CI) 1. 35-2. 88, P < 0. 001, A/H HF (HR 2. 69, 95% CI 1. 92-3. 77, P < 0. 001), cardiogenic shock (HR 1. 46, 95% CI 1. 04-2. 05, P = 0. 029), and CSB (HR 1. 48, 95% CI 1. 22-1. 79, P < 0. 001), but not for MI or stroke, after adjusting for clinical risk factors and prognostic biomarkers. Adding GDF-15 to the model with risk factors and biomarkers improved the net reclassification for CV death, A/H HF, cardiogenic shock, and CSB. CONCLUSIONS: In patients with CAD, admission levels of GDF-15 were associated with an increased 1 year risk of CV death, HF, and bleeding outcomes, but not with thrombotic events. GDF-15 may be a prognostic biomarker for CV death, HF, and bleeding outcomes and could be used to refine the risk assessment of these specific clinical outcomes. TRIAL REGISTRATION: ClinicalTrials. gov Identifier: NCT04044066.